Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 201–300 of 1,006
Predictors of Survival in Mucosal Melanoma of the Head and Neck
Jethanamest, D., Vila, P. M., Sikora, A. G., & Morris, L. G. T. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1685-4 · Cited by 171
Ultraviolet Radiation and Melanoma
Kanavy, H. E., & Gerstenblith, M. R. (2011) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2011.08.003 · Cited by 170
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170
Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
Sekulic, A., Haluska, P., Miller, A. J., De Lamo, J. G., Ejadi, S., Pulido, J. S., Salomao, D. R., Thorland, E. C., Vile, R. G., Swanson, D. L., et al. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.825 · Cited by 148
Oncogene-Directed Alterations in Cancer Cell Metabolism
Nagarajan, A., Malvi, P., & Wajapeyee, N. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.06.002 · Cited by 169
“NRAS mutations are present in approximately 20% of melanomas [19] and acute lymphoblastic leukemias (ALL) [20] and Nagarajan et al.”
BackgroundScolyer, R. A., Long, G. V., & Thompson, J. F. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.03.002 · Cited by 169
Tumor Heterogeneity: Mechanisms and Bases for a Reliable Application of Molecular Marker Design
Diaz-Cano, S. J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021951 · Cited by 169
Melanoma Epidemiology and Prevention
Berwick, M., Buller, D. B., Cust, A. E., Gallagher, R. P., Lee, T. K., Meyskens, F. L., Pandey, S., Thomas, N. E., Veierød, M. B., & Ward, S. V. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_2 · Cited by 170
GLI2-Mediated Melanoma Invasion and Metastasis
Alexaki, V.-I., Javelaud, D., Van Kempen, L. C. L., Mohammad, K. S., Dennler, S., Luciani, F., Hoek, K. S., Juàrez, P., Goydos, J. S., Fournier, P. J., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq257 · Cited by 168
Sosman, J. A., Moon, J., Tuthill, R. J., Warneke, J. A., Vetto, J. T., Redman, B. G., Liu, P. Y., Unger, J. M., Flaherty, L. E., & Sondak, V. K. (2011) · Cancer · doi:10.1002/cncr.26111 · Cited by 168
Tang, B., Chi, Z., Chen, Y., Liu, X., Wu, D., Chen, J., Song, X., Wang, W., Dong, L., Song, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3922 · Cited by 168
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2013) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 167
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms
Arcaini, L., Zibellini, S., Boveri, E., Riboni, R., Rattotti, S., Varettoni, M., Guerrera, M. L., Lucioni, M., Tenore, A., Merli, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-368209 · Cited by 167
Lu, M., Breyssens, H., Salter, V., Zhong, S., Hu, Y., Baer, C., Ratnayaka, I., Sullivan, A., Brown, N. R., Endicott, J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.013 · Cited by 166
Ipilimumab for Patients With Advanced Mucosal Melanoma
Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N., Panageas, K. S., Lawrence, D. P., Ibrahim, N., Flaherty, K. T., Sullivan, R. J., Ott, P. A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0464 · Cited by 166
Garibyan, L., & Fisher, D. E. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0119-y · Cited by 170
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Ibrahim, N., & Haluska, F. G. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151541 · Cited by 138
Prognosis of Acral Melanoma: A Series of 281 Patients
Bello, D. M., Chou, J. F., Panageas, K. S., Brady, M. S., Coit, D. G., Carvajal, R. D., & Ariyan, C. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3089-0 · Cited by 168
Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma
Siroy, A. E., Boland, G. M., Milton, D. R., Roszik, J., Frankian, S., Malke, J. C., Haydu, L. E., Prieto, V. G., Tetzlaff, M. T., Ivan, D. S., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.366 · Cited by 166
Analysis of the genome to personalize therapy for melanoma
Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 165
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
Goel, V. K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F. S., Hinds, P. W., & Haluska, F. G. (2009) · Oncogene · doi:10.1038/onc.2009.95 · Cited by 165
Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment
Markovic, S. N., Erickson, L. A., Rao, R. D., Weenig, R. H., Pockaj, B. A., Bardia, A., Vachon, C. M., Schild, S. E., McWilliams, R. R., Hand, J. L., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.4.490 · Cited by 165
Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
Gellrich, F. F., Schmitz, M., Beissert, S., & Meier, F. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010223 · Cited by 165
A brief history of melanoma: from mummies to mutations
Rebecca, V. W., Sondak, V. K., & Smalley, K. S. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328351fa4d · Cited by 163
Whole genome sequencing of matched primary and metastatic acral melanomas
Turajlic, S., Furney, S. J., Lambros, M. B., Mitsopoulos, C., Kozarewa, I., Geyer, F. C., MacKay, A., Hakas, J., Zvelebil, M., Lord, C. J., et al. (2012) · Genome Research · doi:10.1101/gr.125591.111 · Cited by 163
Melanoma: Molecular pathogenesis and emerging target therapies (Review)
Libra (2009) · International Journal of Oncology · doi:10.3892/ijo_00000277 · Cited by 136
Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation
Zeng, H., Jorapur, A., Shain, A. H., Lang, U. E., Torres, R., Zhang, Y., McNeal, A. S., Botton, T., Lin, J., Donne, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.014 · Cited by 137
Self-citationNRAS-mutant melanoma: current challenges and future prospect
Muñoz-Couselo, E., Zamora Adelantado, E., Ortiz Vélez, C., Soberino-García, J., & Perez-Garcia, J. M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s117121 · Cited by 162
The genome and epigenome of malignant melanoma
DAHL, C., & GULDBERG, P. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_855.xml.x · Cited by 162
“Proto-oncogenes NRAS Mutation 15–25 (10–16, 84) BRAF Mutation 50–70 (21–24, 84) KIT Mutation 2–10 (37, 38) CDK4 Mutation, amplification 0–9 (47, 48, 56, 84, 126) CTNNB1 Mutation 2–23 (84, 95–101) MITF Amplification 10–16 (84, 105) CCND1 Amplification 6–44 (55, 84, 127) PIK3CA Mutation 5 (76, 77) AKT3 Amplification 40–…”
KRAS and BRAF: drug targets and predictive biomarkers
Vakiani, E., & Solit, D. B. (2011) · The Journal of Pathology · doi:10.1002/path.2796 · Cited by 162
Update on primary mucosal melanoma
Tacastacas, J. D., Bray, J., Cohen, Y. K., Arbesman, J., Kim, J., Koon, H. B., Honda, K., Cooper, K. D., & Gerstenblith, M. R. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.031 · Cited by 162
Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases
Turri‐Zanoni, M., Medicina, D., Lombardi, D., Ungari, M., Balzarini, P., Rossini, C., Pellegrini, W., Battaglia, P., Capella, C., Castelnuovo, P., et al. (2012) · Head & Neck · doi:10.1002/hed.23079 · Cited by 162
Self-citationHuman tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma
Ablain, J., Xu, M., Rothschild, H., Jordan, R. C., Mito, J. K., Daniels, B. H., Bell, C. F., Joseph, N. M., Wu, H., Bastian, B. C., et al. (2018) · Science · doi:10.1126/science.aau6509 · Cited by 142
Self-citationTasdogan, A., Sullivan, R. J., Katalinic, A., Lebbé, C., Whitaker, D., Puig, S., van de Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00603-8 · Cited by 169
Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management
Postow, M. A., Hamid, O., & Carvajal, R. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0244-x · Cited by 161
Wong, K., van der Weyden, L., Schott, C. R., Foote, A. K., Constantino‐Casas, F., Smith, S., Dobson, J. M., Murchison, E. P., Wu, H. G., Yeh, I., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08081-1 · Cited by 161
Self-citationGenetic alterations of PTEN in human melanoma
Aguissa-Touré, A.-H., & Li, G. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0878-0 · Cited by 160
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma
Simpson, R. M., Bastian, B. C., Michael, H. T., Webster, J. D., Prasad, M. L., Conway, C. M., Prieto, V. M., Gary, J. M., Goldschmidt, M. H., Esplin, D. G., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12185 · Cited by 160
Self-citationMolecular biology of normal melanocytes and melanoma cells
Bandarchi, B., Jabbari, C., Vedadi, A., & Navab, R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201471 · Cited by 160
Targeted Therapy and Immunotherapy for Melanoma in Japan
Namikawa, K., & Yamazaki, N. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0607-8 · Cited by 159
Targeting BRAF for patients with melanoma
Arkenau, H., Kefford, R. F., & Long, G. V. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606030 · Cited by 159
Frequent mutations in the MITF pathway in melanoma
Cronin, J. C., Wunderlich, J., Loftus, S. K., Prickett, T. D., Wei, X., Ridd, K., Vemula, S., Burrell, A. S., Agrawal, N. S., Lin, J. C., et al. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00578.x · Cited by 158
Self-citationGenetic and morphologic features for melanoma classification
Broekaert, S. M. C., Roy, R., Okamoto, I., van den Oord, J., Bauer, J., Garbe, C., Barnhill, R. L., Busam, K. J., Cochran, A. J., Cook, M. G., et al. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00778.x · Cited by 158
Self-citationEfficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
Del Vecchio, M., Di Guardo, L., Ascierto, P. A., Grimaldi, A. M., Sileni, V. C., Pigozzo, J., Ferraresi, V., Nuzzo, C., Rinaldi, G., Testori, A., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.007 · Cited by 158
“Additional studies support this observation [12,13]; however, in an analysis of another 20 mucosal melanomas, BRAF and NRAS mutations were detected in 11% and 5% of tumours, respectively [14].”
ResultVemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
Sapkota, B., Hill, C. E., & Pollack, B. P. (2013) · OncoImmunology · doi:10.4161/onci.22890 · Cited by 158
Darmawan, C. C., Jo, G., Montenegro, S. E., Kwak, Y., Cheol, L., Cho, K. H., & Mun, J. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.081 · Cited by 158
Self-citationBiomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma
Khoja, L., Lorigan, P. C., Zhou, C., Lancashire, M., Booth, J., Cummings, J., Califano, R., Clack, G., Hughes, A. M., & Dive, C. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.468 · Cited by 156
NF 1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
Cirenajwis, H., Lauss, M., Ekedahl, H., Törngren, T., Kvist, A., Saal, L. H., Olsson, H. L., Staaf, J., Carneiro, A., Ingvar, C., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12050 · Cited by 156
Reactive oxygen species in melanoma and its therapeutic implications
Wittgen, H. G. M., & van Kempen, L. C. L. T. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e3282f1d312 · Cited by 143
Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma
Gammons, M. V. R., Lucas, R., Dean, R., Coupland, S. E., Oltean, S., & Bates, D. O. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.342 · Cited by 157
Basurto‐Lozada, P., Molina‐Aguilar, C., Castaneda‐Garcia, C., Vázquez‐Cruz, M. E., Garcia‐Salinas, O. I., Álvarez‐Cano, A., Martínez‐Said, H., Roldán‐Marín, R., Adams, D. J., Possik, P. A., et al. (2021) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12885 · Cited by 154
“Oncogenic activation of the CDK4 pathway through copy-number gains in CDK4, CCND1 and loss of CDKN2A is a common genetic feature of acral melanomas (Bastian et al., 2000; Curtin et al., 2005; Furney et al., 2012; Kong et al., 2017; Liang et al., 2017).”
BackgroundResultIntegrated genomic analyses reveal frequent TERT aberrations in acral melanoma
Liang, W. S., Hendricks, W. P. D., Kiefer, J., Schmidt, J. E., Sekar, S., Carpten, J. D., Craig, D. W., Adkins, J. R., Cuyugan, L., Manojlovic, Z., et al. (2017) · Genome Research · doi:10.1101/gr.213348.116 · Cited by 154
Self-citationMar, V., Wong, S. Q., Li, J., Scolyer, R. A., McLean, C., Papenfuss, A. T., Tothill, R. W., Kakavand, H., Mann, G. J., Thompson, J. F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0398 · Cited by 152
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies, A. M., & Long, G. V. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70072-5 · Cited by 152
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors
Grimaldi, A. M., Simeone, E., Festino, L., Vanella, V., Strudel, M., & Ascierto, P. A. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0292-y · Cited by 152
Melanoma of the hand and foot: epidemiological, prognostic and genetic features. A systematic review
Durbec, F., Martin, L., Derancourt, C., & Grange, F. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10772.x · Cited by 153
Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
Woodman, S. E., & Davies, M. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.032 · Cited by 151
Nakamura, Y., Namikawa, K., Yoshino, K., Yoshikawa, S., Uchi, H., Goto, K., Nakamura, Y., Fukushima, S., Kiniwa, Y., Takenouchi, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.031 · Cited by 150
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries
Brown, N. A., & Betz, B. L. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29329 · Cited by 149
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
Newell, F., Johansson, P. A., Wilmott, J. S., Nones, K., Lakis, V., Pritchard, A. L., Lo, S., Rawson, R. V., Kazakoff, S. H., Colebatch, A. J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0603 · Cited by 152
Ozols, R. F., Herbst, R. S., Colson, Y. L., Gralow, J. R., Bonner, J., Curran, W. J., Eisenberg, B. L., Ganz, P. A., Kramer, B. S., Kris, M. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7030 · Cited by 149
The roles of microphthalmia-associated transcription factor and pigmentation in melanoma
Hsiao, J. J., & Fisher, D. E. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.019 · Cited by 148
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas
Ashida, A., Takata, M., Murata, H., Kido, K., & Saida, T. (2008) · International Journal of Cancer · doi:10.1002/ijc.24048 · Cited by 148
The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis
Furney, S. J., Turajlic, S., Stamp, G., Thomas, J., Hayes, A. J., Strauß, D., Gavrielides, M., Xing, W., Gore, M. E., Larkin, J., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12279 · Cited by 147
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 148
UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer
Liu-Smith, F., Jia, J., & Zheng, Y. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-56017-5_3 · Cited by 147
Epidemiology, Risk Factors, Prevention, and Early Detection of Melanoma
Azoury, S. C., & Lange, J. R. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.07.013 · Cited by 148
Cutaneous melanoma in the era of molecular profiling
Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61397-0 · Cited by 146
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
Menzer, C., Menzies, A. M., Carlino, M. S., Reijers, I. L. M., Groen, E. J., Eigentler, T., de Groot, J. W. B., van der Veldt, A. A. M., Johnson, D. B., Meiß, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00489 · Cited by 145
Mucosal Melanomas: A Case-Based Review of the Literature
Seetharamu, N., Ott, P. A., & Pavlick, A. C. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0067 · Cited by 144
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
Knauf, J. A., & Fagin, J. A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.013 · Cited by 143
Vergier, B., Prochazkova‐Carlotti, M., de la Fouchardière, A., Cerroni, L., Massi, D., GIORGI, V. D., Bailly, C., Wesselmann, U., Karlseladze, A., Avril, M., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.228 · Cited by 142
PTEN mutation, methylation and expression in breast cancer patients
Zhang, H., LIANG, F., Zhi-ling, J., Song, S., & Jiang, Z. (2013) · Oncology Letters · doi:10.3892/ol.2013.1331 · Cited by 142
Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene
Khodadoust, M. S., Verhaegen, M., Kappes, F., Riveiro-Falkenbach, E., Cigudosa, J. C., Kim, D. S. L., Chinnaiyan, A. M., Markovitz, D. M., & Soengas, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1063 · Cited by 135
Catalanotti, F., Solit, D. B., Pulitzer, M. P., Berger, M. F., Scott, S. N., Iyriboz, T., Lacouture, M. E., Panageas, K. S., Wolchok, J. D., Carvajal, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3476 · Cited by 135
Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies
Saldanha, G. S., Potter, L., DaForno, P., & Pringle, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2447 · Cited by 141
Verhaegen, M., Bauer, J. A., Martín de la Vega, C., Wang, G., Wolter, K. G., Brenner, J. C., Nikolovska-Coleska, Z., Bengtson, A., Nair, R., Elder, J. T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1748 · Cited by 140
“expression during malignant transformation (4, 5).”
Developmental pathways activated in melanocytes and melanoma
Liu, J., Fukunaga‐Kalabis, M., Li, L., & Herlyn, M. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.023 · Cited by 142
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Jiang, X., Zhou, J., Yuen, N. K., Corless, C. L., Heinrich, M. C., Fletcher, J. A., Demetri, G. D., Widlund, H. R., Fisher, D. E., & Hodi, F. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1144 · Cited by 140
Hou, J. Y., Baptiste, C. D., Hombalegowda, R. B., Tergas, A. I., Feldman, R. A., Jones, N., Chatterjee‐Paer, S., Bus‐Kwolfski, A., Wright, J. D., & Burke, W. M. (2016) · Cancer · doi:10.1002/cncr.30473 · Cited by 140
Key points in dermoscopic differentiation between early acral melanoma and acral nevus
Saida, T., Koga, H., & Uhara, H. (2010) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2010.01174.x · Cited by 142
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 140
Melanoma: Differences between Asian and Caucasian Patients
Lee, H. Y., Chay, W. Y., Tang, M. B. Y., Chio, M. T., & Tan, S. H. (2012) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v41n1p17 · Cited by 140
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
BRAF, a target in melanoma: Implications for solid tumor drug development
Flaherty, K. T., & McArthur, G. A. (2010) · Cancer · doi:10.1002/cncr.25261 · Cited by 139
Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects
Küsters‐Vandevelde, H. V. N., Küsters, B., Grunsven, A. C. H. V. E., Groenen, P. J. T. A., Wesseling, P., & Blokx, W. A. M. (2014) · Brain Pathology · doi:10.1111/bpa.12241 · Cited by 139
The p16INK4A tumor suppressor regulates cellular oxidative stress
Jenkins, N. C., Liu, T., Cassidy, P., Leachman, S. A., Boucher, K. M., Goodson, A. G., Samadashwily, G., & Grossman, D. (2011) · Oncogene · doi:10.1038/onc.2010.419 · Cited by 138
“The Cdkn2a locus regulates oxidative stress in vivo The p16-encoding Cdkn2a locus is mutated in approximately half of the familial melanoma cases (Curtin et al., 2005).”
BackgroundInfluentialTargeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer
Zhang, P., Kawakami, H., Liu, W., Zeng, X., Strebhardt, K., Tao, K., Huang, S., & Sinicrope, F. A. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0404 · Cited by 138
Handolias, D., Salemi, R., Murray, W. K., Tan, A., Liu, W. J., Virós, A., Dobrovic, A., Kelly, J. W., & McArthur, G. A. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00671.x · Cited by 138
Romano, E., Pradervand, S., Paillusson, A., Weber, J., Harshman, K., Muehlethaler, K., Speiser, D., Peters, S., Rimoldi, D., & Michielin, O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0661 · Cited by 130
Jin, J., Wu, X., Yin, J., Li, M., Shen, J., Li, J., Zhao, Y., Zhao, Q., Wu, J., Wen, Q., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00263 · Cited by 138
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
Schilling, B., Sucker, A., Griewank, K., Zhao, F., Weide, B., Görgens, A., Giebel, B., Schadendorf, D., & Paschen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28168 · Cited by 125
Gaiser, T., Kutzner, H., Palmedo, G., Siegelin, M. D., Wiesner, T., Bruckner, T. M., Hartschuh, W., Enk, A., & Becker, M. R. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.177 · Cited by 136
Self-citationMelanomas and Mechanical Stress Points on the Plantar Surface of the Foot
Minagawa, A., Omodaka, T., & Okuyama, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1512354 · Cited by 136
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
AbuHammad, S., Cullinane, C. M., Martin, C., Bacolas, Z., Ward, T. A., Chen, H., Slater, A. A., Ardley, K., Kirby, L., Chan, K. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901323116 · Cited by 138
Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma
Solomon, D. A., Kim, J.-S., Cronin, J. C., Sibenaller, Z., Ryken, T., Rosenberg, S. A., Ressom, H., Jean, W., Bigner, D., Yan, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-3272 · Cited by 126
Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Zhou, R., Shi, C., Tao, W., Li, J., Wu, J., Han, Y., Yang, G., Gu, Z., Xu, S., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3442 · Cited by 135
Laikova, K. V., Oberemok, V. V., Krasnodubets, A. M., Gal’chinsky, N. V., Useinov, R. Z., Novikov, I. A., Temirova, Z. Z., Владимирович, Г. М., Shved, N. A., Kumeiko, V. V., et al. (2019) · Molecules · doi:10.3390/molecules24081516 · Cited by 134
The GIST paradigm: lessons for other kinase‐driven cancers
Antonescu, C. R. (2010) · The Journal of Pathology · doi:10.1002/path.2798 · Cited by 133
A Review of Epidemiology and Cancer Biology of Malignant Melanoma
Davey, M. G., Miller, N., & McInerney, N. M. (2021) · Cureus · doi:10.7759/cureus.15087 · Cited by 134
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.